Articles
  

Effect of HLA-B*27 and its Subtypes on Clinical Manifestations and Severity of Ankylosing Spondylitis in Iranian Patients

Abstract

The aim of this study was to assess the role of HLA-B*27 and it’s subtypes in determining severity and clinical manifestations of ankylosing spondylitis (AS).
A total of 163 AS patients were assessed for clinical manifestations and severity using structured questionnaires. HLA-B*27 screening and B*27 sub-typing were performed by PCR.
One hundred twenty two patients (74.8%) were B*27 positive. The male to female ratio, peripheral arthritis, steroid use, intense dorsal kyphosis and decrease of cervical slope had a significantly higher frequency in B*27 positive patients  compared  to  B*27 negative ones (p=0.01,  0.001,  0.01,  0.04  and  0.04,  respectively). However,  the  age  of  diagnosis  was significantly lower in B*27 positive patients (p=0.005). Trend in uveitis and some severity markers including: BASMI and ASQoL were toward higher values in B*27 positive group with no significant difference. After controlling confounding variables, significant relationship was found  only between B*27 and BASMI (p=0.01). B*27 subtypes in patients were included B*2705: 48.4%, B*2702: 42.6%, B*2704: 5.7% and B*2707: 3.3%. No significant differences were seen for severity markers and clinical manifestations between subtypes; although trend toward lower values of severity markers, less intense dorsal kyphosis and less decrease of cervical slope were observed in B*2704 and B*2707 versus other polymorphisms.
Clinical features and severity of AS is influenced by HLA-B*27. Trend  toward higher severity markers in B*2705 and B*2702 versus other  polymorphisms might be subject of interest for evaluation in other ethnicities with concentration to other novel susceptibility genes co-inherited in each B*27 subtype.

1. Fallahi S, Jamshidi A, Gharibdoost F, Mahmoudi M, Paragomi P, Nicknam M, et al. Urolithiasis in ankylosing spondylitis: Correlation with Bath ankylosing spondylitis disease activity index (BASDAI), Bath ankylosing Clinical Correlations of HLA-B*27 Polymorphisms in Ankylosing Spondylitis spondylitis functional index (BASFI) and Bath ankylosing spondylitis metrology index (BASMI). Caspian J Intern Med 2012; 3(4):508-13.
2. Boonen A. A review of work -participation, cost- of- illness and cost-effectiveness studies in ankylosing spondylitis. Nat Clin Pract Rheumatol 2006; 2(10):546-53.
3. Martindale J, Smith J, Sutton CJ, Grennan D, Goodacre L, Goodacre JA. Disease and psychological status in ankylosing spondyklitis. Rheumatology (Oxford) 2006;45(10):1288-93.
4. Ozgül A, peker F, Taskaynatan M, Tan AK, Dinçer K, kalyon TA. Effect of ankylosig spondylitis on health- related quality of life and different aspects of social life in young patients. Clin Rheumatol 2006;25(2):168-74.
5. van Echteld I, Cieza A, Boonen A, Stucki G, Zochling J, Braun J, et al. Identification of the most common problems by patients with ankylosing spondylitis using the International Cassification of Functionning, Disability and Health. J Rheumatol 2006; 33(12):2475-83.
6. Smith JA, Märker-Hermann E, Colbert RA. Pathogenesis of ankylosing spondylitis: current concepts. Best Pract Res Clin Rheumatol 2006; 20(3):571-91.
7. Thomas GP, Brown MA. Genetics and genomics of ankylosing spondylitis. Immunol Rev 2010; 233(1):162-80.
8. Sheehan NJ. HLA-B27: what's new? Rheumatology (Oxford) 2010; 49(4):621-31.
9. Khan MA. Remarkable polymorphism of HLA-B27: an ongoing saga. Curr Rheumatol Rep 2010; 12(5):337-41.
10. MacLean I, Iqball S, Woo P, Keat AC, Hughs RA, Kingsley GH, et al. HLA-B27 subtypes in spondyloarthropathies. Clin Exp Immunol 1993;91(2):214-9.
11. Cipriani A, Rivera S, Hassanhi M, Márquez G, Hernández R, Villalobos C, et al. HLA-B27 subtypes determination in patients with ankylosing spondylitis from Zulia, Venezuela. Hum Immunol 2003; 64(7):745-9.
12. Acar M, Cora T, Tunc R, Acar H. HLA-B27 subtypes in Turkish patients with ankylosing spondylitis and healthy controls. Rheumatol Int 2012; 32(10):3103-5.
13. Chavan H, Samant R, Deshpande A, Mankeshwar R.Correlation of HLA B27 subtypes with clinical features of ankylosing spondylitis. Int J Rheum Dis 2011;14(4):369-74.
14. Harfouch EI, Al-Cheikh SA. HLA-B27 and its subtypes in Syrian patients with ankylosing spondylitis. Saudi Med J 2011; 32(4):364-8.
15. Nicknam MH, Mahmoudi M, Amirzargar AA, Ganjalikhani Hakemi M, Khosravi F, Jamshidi AR, et al. Determination of HLA-B27 subtypes in Iranian patients with ankylosing spondylitis. Iran J Allergy Asthma Immunol 2008; 7(1):19-24.
16. Oguz FS, Ocal L, Diler AS, Ozkul H, Asicioglu F, Kasapoglu E, et al. HLA B-27 subtypes in Turkish patients with spondyloarthropathy and healthy controls. Dis Markers 2004; 20(6):309-12.
17. Park SH, Kim J, Kim SG, Kim SK, Chung WT, Choe JY.Human Leukocyte antigen-B27 subtypes in Korean patients with ankylosing spondylitis: higher B*2705 in the patient group. Int J Rheum Dis 2009; 12(1):34-8.
18. Zhang S, Li Y, Deng X, Huang F. Similarities and differences between spondyloarthritis in Asia and other parts of the world. Curr Opin Rheumatol 2011;23(4):334-8.
19. Dhaliwal JS, Too CL, Lisut M, Lee YY, Murad S. HLA- B27 polymorphism in the Malays. Tissue Antigens 2003;62(4):330-2.
20. Brown MA, Brophy S, Bradbury L, Hamersma J, Timms A, Laval S, et al. Identification of major loci controlling clinical manifestations of ankylosing spondylitis. Arthritis Rheum 2003; 48(8):2234-9.
21. Brown MA, Kennedy LG, Darke C, Gibson K, Pile KD, Shatford JL, et al. The effect of HLA-DR genes on susceptibility to and severity of ankylosing spondylitis. Arthritis Rheum 1998; 41(3):460-5.
22. Vargas-Alarcón G, Londoño JD, Hernández-Pacheco G,Pacheco-Tena C, Castillo E, Cardiel MH, et al. Effect of HLA-B and HLA-DR genes on susceptibility to and severity of spondyloarthritis in Mexican patients. Ann Rheum Dis 2002; 61(8):714-7.
23. Freeston J, Barkham N, Hensor E, Emery P, Fraser A. Ankylosing spondylitis, HLA-B27 positivity and the need for biologic therapies. Joint Bone Spine 2007; 74(2):140-3.
24. Jaakkola E, Herzberg I, Laiho K, Barnardo MC, Pointon JJ, Kauppi M, et al. Finnish HLA studies confirm the increased risk conferred by HLA-B27 homozygosity in ankylosing spondylitis. Ann Rheum Dis 2006; 65(6):775-80.
25. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27(4):361-8.
26. Garret S, Jekinson T, Kennedy LG, Withlock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath ankylosing spondylitis disease activity index. J Rheumatol 1994; 21(12):2286-91.
27. Calin A, Garrett S, Withelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional index. J Rheumatol 1994; 21(12):2281-5.
28. van der Heijde D, Landewé R, Feldtkeller E. Proposal of a linear definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2- step and 10-step definitions. Ann Rheum Dis 2008;67(4):489-93.
29. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994; 21(9):1694-8.
30. Jones SD, Steiner A, Garrett SL, Calin A. The BathAnkylosing Spondylitis Patient Global Score (BAS-G). Br J Rheumatol 1996; 35(1):66-71.
31. Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwel PS, Kay LJ, et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 2003; 62(1):20-6.
32. Bidad K, Fallahi S, Mahmoudi M, Jamshidi A, Farhadi E,Meysamie A, et al. Evaluation of the Iranian versions of the Bath Ankylosing Spondylitis Disease activity index (BASDAI), the Bath Ankylosing Spondylitis Functional index (BASFI) and the Patient Acceptable Symptom State (PASS) in patients with ankylosing spondylitis. Rheumatol Int 2012; 32(11):3613-8.
33. Linssen A. B27+ disease versus B27- disease. Scand J Rheumatol Suppl 1990; 87:111-8.
34. Feldtkller E, Khan MA, van der Hijde D, van der Linden S, Braun J. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 2003; 23(2):61-6.
35. Khan MA, Kushner I, Braun WE. Comparison of clinical features in HLA-B27 positive and negative patients with ankylosing spondylitis. Arthritis Rheum 1977; 20(4):909-12.
36. Wu Z, Lin Z, Wei Q, Gu J. Clinical features of ankylosing spondylitis may correlate with HLA-B27 pol

Files
IssueVol 12, No 4 (2013) QRcode
SectionArticles
Keywords
Ankylosing Spondylitis Clinical manifestations HLA-B*27 HLA-B*2705
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Fallahi S, Mahmoudi M, Nicknam MH, Gharibdoost F, Farhadi E, Saei A, Nourijelyani K, Ahmadzadeh N, Jamshidi AR. Effect of HLA-B*27 and its Subtypes on Clinical Manifestations and Severity of Ankylosing Spondylitis in Iranian Patients. Iran J Allergy Asthma Immunol. 1;12(4):321-330.